INmune Bio
INMB
34 hedge funds and large institutions have $10.3M invested in INmune Bio in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
165% more call options, than puts
Call options by funds: $443K | Put options by funds: $167K
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
3% more funds holding
Funds holding: 33 → 34 (+1)
1.49% less ownership
Funds ownership: 10.67% → 9.18% (-1.5%)
12% less capital invested
Capital invested by funds: $11.7M → $10.3M (-$1.43M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$206K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$113K |
| 3 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
+$96.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$36.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$894K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$247K |
| 3 |
Millennium Management
New York
|
-$74.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$67.3K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$36K |
INMB Hedge Fund Activity: Q4 2022 in Review
34 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2022, worth a combined $10.3M — down 12% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new INMB positions and 1 closed out — a net gain of 3 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Janney Montgomery Scott, adding an estimated $206K. The largest seller was Morgan Stanley, cutting an estimated $894K.
- 34 institutional investors held INmune Bio (INMB) as of Q4 2022, up from 33 in Q3 2022.
- Funds reported $10.3M of INmune Bio stock for Q4 2022, down 12% quarter-over-quarter.
- 4 funds opened new INmune Bio positions in Q4 2022 and 1 closed out, a net change of +3 holders.
- The largest INmune Bio buyer in Q4 2022 was Janney Montgomery Scott, an estimated $206K added.
- The largest INmune Bio seller in Q4 2022 was Morgan Stanley, an estimated $894K sold.
Based on aggregated 13F filings for Q4 2022.